Alexandria Forbes

MeiraGTx is a vertically integrated, clinical-stage gene therapy company with core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Forbes founded MeiraGTx in 2015 with a vision of building a unique, end-to-end, vertically integrated approach to gene therapy, with clinical programs in diseases of the eye, salivary gland, and central nervous system. In a landmark result, MeiraGTx's gene therapy restored visual function in all 11 children born blind who received it in a clinical trial, prompting the company to pursue expedited regulatory approval.

Before founding MeiraGTx, Forbes spent ten years as a healthcare investor at Sivik Global Healthcare and Meadowvale Asset Management, two healthcare hedge funds, where she developed deep expertise in biotechnology, specialty pharmaceuticals, and diagnostics. Prior to that she served as a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, and held research fellowships at Duke University and the Carnegie Institute at Johns Hopkins University. She received her Ph.D. in Molecular Genetics from Oxford University and her M.A. in Natural Sciences from Cambridge University. Forbes was named to Forbes Media's 50 Over 50 class in the innovation category in 2023.